Clinical course of recurrent genital herpes and treatment with foscarnet cream: Results of a Canadian multicenter trial

Stephen L. Sacks; Joseph Portnoy; David Lawee; Walter Schlech; Fred Y. Aoki; David L. Tyrrell; Michael Poisson; Cathy Bright; Jacob Kaluski

doi:10.1093/infdis/155.2.178

Clinical course of recurrent genital herpes and treatment with foscarnet cream: Results of a Canadian multicenter trial

Stephen L. Sacks, Joseph Portnoy, David Lawee, Walter Schlech, Fred Y. Aoki, David L. Tyrrell, Michael Poisson, Cathy Bright, Jacob Kaluski

Résultat de recherche: Article › examen par les pairs

29 Citations (Scopus)

Résumé

Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0.3% in men and 1% in women) was compared with a placebo in a Canadian multicenter trial involving 309 patients. Culture-positive episodes of herpes took significantly longer to heal than did the others. Lesions in men were larger and lasted longer but were less symptomatic than those in women. Foscarnet did not statistically improve the times to healing or the loss of symptoms overall but did result in a higher proportion of symptom-free individuals after one day of treatment. Foscarnet-treated patients had a reduced duration of shedding of virus, and this was significant for men. These clinical benefits do not, however, warrant general use of this agent for established lesions. Earlier, prodromal treatment might have been more effective, but patient-initiated studies include a greater proportion of culture-negative (shorter) episodes that often make results difficult to interpret.

Langue d'origine	English
Pages (de-à)	178-186
Nombre de pages	9
Journal	Journal of Infectious Diseases
Volume	155
Numéro de publication	2
DOI	https://doi.org/10.1093/infdis/155.2.178
Statut de publication	Published - 1987
Publié à l'externe	Oui

Note bibliographique

Funding Information:
Received for publication 16 January 1986, and in revised form 23 June 1986. The members of the study group included the following: Nancy P. Reudy, Megan O'Connor, and Marika A. Sacks, University of British Columbia, Vancouver; Andrew Taussig, the Microbiology Laboratory Clinic, Montreal; Philip Scappatura and Barbara Greenberg, University of Toronto, Toronto; Nancy Meagher, Victoria General Hospital, Halifax, Nova Scotia; Zenaida Dela Cruz, Gregory W. Hammond, Bernard A. O. Binns, R. Grant Benningen, and Aileen Yap, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba; Lori Zapernick, University of Alberta, Edmonton, Alberta; Richard Morriset, Denis Phaneuf, and Carlos Vega, Hotel Dieu Hospital, Montreal, Quebec. Written, informed consent was obtained from all participants before the study, in accordance with the guidelines established by each center's independent review board and by Health and Welfare, Canada. This work was supported in part by Astra Pharmaceuticals Canada, Limited, Mississauga, Ontario.

ASJC Scopus Subject Areas

Immunology and Allergy
Infectious Diseases

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1093/infdis/155.2.178

Autres fichiers et liens

Citer

@article{982e6edfc49346078857ff57b4300c24,

title = "Clinical course of recurrent genital herpes and treatment with foscarnet cream: Results of a Canadian multicenter trial",

abstract = "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0.3% in men and 1% in women) was compared with a placebo in a Canadian multicenter trial involving 309 patients. Culture-positive episodes of herpes took significantly longer to heal than did the others. Lesions in men were larger and lasted longer but were less symptomatic than those in women. Foscarnet did not statistically improve the times to healing or the loss of symptoms overall but did result in a higher proportion of symptom-free individuals after one day of treatment. Foscarnet-treated patients had a reduced duration of shedding of virus, and this was significant for men. These clinical benefits do not, however, warrant general use of this agent for established lesions. Earlier, prodromal treatment might have been more effective, but patient-initiated studies include a greater proportion of culture-negative (shorter) episodes that often make results difficult to interpret.",

author = "Sacks, {Stephen L.} and Joseph Portnoy and David Lawee and Walter Schlech and Aoki, {Fred Y.} and Tyrrell, {David L.} and Michael Poisson and Cathy Bright and Jacob Kaluski",

note = "Funding Information: Received for publication 16 January 1986, and in revised form 23 June 1986. The members of the study group included the following: Nancy P. Reudy, Megan O'Connor, and Marika A. Sacks, University of British Columbia, Vancouver; Andrew Taussig, the Microbiology Laboratory Clinic, Montreal; Philip Scappatura and Barbara Greenberg, University of Toronto, Toronto; Nancy Meagher, Victoria General Hospital, Halifax, Nova Scotia; Zenaida Dela Cruz, Gregory W. Hammond, Bernard A. O. Binns, R. Grant Benningen, and Aileen Yap, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba; Lori Zapernick, University of Alberta, Edmonton, Alberta; Richard Morriset, Denis Phaneuf, and Carlos Vega, Hotel Dieu Hospital, Montreal, Quebec. Written, informed consent was obtained from all participants before the study, in accordance with the guidelines established by each center's independent review board and by Health and Welfare, Canada. This work was supported in part by Astra Pharmaceuticals Canada, Limited, Mississauga, Ontario.",

year = "1987",

doi = "10.1093/infdis/155.2.178",

language = "English",

volume = "155",

pages = "178--186",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Clinical course of recurrent genital herpes and treatment with foscarnet cream

T2 - Results of a Canadian multicenter trial

AU - Sacks, Stephen L.

AU - Portnoy, Joseph

AU - Lawee, David

AU - Schlech, Walter

AU - Aoki, Fred Y.

AU - Tyrrell, David L.

AU - Poisson, Michael

AU - Bright, Cathy

AU - Kaluski, Jacob

N1 - Funding Information: Received for publication 16 January 1986, and in revised form 23 June 1986. The members of the study group included the following: Nancy P. Reudy, Megan O'Connor, and Marika A. Sacks, University of British Columbia, Vancouver; Andrew Taussig, the Microbiology Laboratory Clinic, Montreal; Philip Scappatura and Barbara Greenberg, University of Toronto, Toronto; Nancy Meagher, Victoria General Hospital, Halifax, Nova Scotia; Zenaida Dela Cruz, Gregory W. Hammond, Bernard A. O. Binns, R. Grant Benningen, and Aileen Yap, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba; Lori Zapernick, University of Alberta, Edmonton, Alberta; Richard Morriset, Denis Phaneuf, and Carlos Vega, Hotel Dieu Hospital, Montreal, Quebec. Written, informed consent was obtained from all participants before the study, in accordance with the guidelines established by each center's independent review board and by Health and Welfare, Canada. This work was supported in part by Astra Pharmaceuticals Canada, Limited, Mississauga, Ontario.

PY - 1987

Y1 - 1987

N2 - Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0.3% in men and 1% in women) was compared with a placebo in a Canadian multicenter trial involving 309 patients. Culture-positive episodes of herpes took significantly longer to heal than did the others. Lesions in men were larger and lasted longer but were less symptomatic than those in women. Foscarnet did not statistically improve the times to healing or the loss of symptoms overall but did result in a higher proportion of symptom-free individuals after one day of treatment. Foscarnet-treated patients had a reduced duration of shedding of virus, and this was significant for men. These clinical benefits do not, however, warrant general use of this agent for established lesions. Earlier, prodromal treatment might have been more effective, but patient-initiated studies include a greater proportion of culture-negative (shorter) episodes that often make results difficult to interpret.

AB - Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0.3% in men and 1% in women) was compared with a placebo in a Canadian multicenter trial involving 309 patients. Culture-positive episodes of herpes took significantly longer to heal than did the others. Lesions in men were larger and lasted longer but were less symptomatic than those in women. Foscarnet did not statistically improve the times to healing or the loss of symptoms overall but did result in a higher proportion of symptom-free individuals after one day of treatment. Foscarnet-treated patients had a reduced duration of shedding of virus, and this was significant for men. These clinical benefits do not, however, warrant general use of this agent for established lesions. Earlier, prodromal treatment might have been more effective, but patient-initiated studies include a greater proportion of culture-negative (shorter) episodes that often make results difficult to interpret.

UR - http://www.scopus.com/inward/record.url?scp=0023152616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023152616&partnerID=8YFLogxK

U2 - 10.1093/infdis/155.2.178

DO - 10.1093/infdis/155.2.178

M3 - Article

AN - SCOPUS:0023152616

SN - 0022-1899

VL - 155

SP - 178

EP - 186

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -

Clinical course of recurrent genital herpes and treatment with foscarnet cream: Results of a Canadian multicenter trial

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer